Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
This study aimed to analyze four current pathways affecting the listing and post-listing prices of new orphan drugs (ODs) in South Korea. These mechanisms were: (1) essential OD, (2) pharmacoeconomic evaluation (PE) waiver OD, (3) weighted average price OD, and (4) PE OD. We analyzed the ratio of th...
Main Author: | Jong Hyuk Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Healthcare |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9032/9/3/296 |
Similar Items
-
Price increase negotiations to address drug shortages in South Korea’s national health insurance
by: Seung Rae Yu, et al.
Published: (2023-12-01) -
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01) -
Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01) -
Public spending on orphan medicines: a review of the literature
by: Margit Gombocz, et al.
Published: (2020-12-01)